key: cord-0980312-wqc4o648
authors: Marson, Piero; Cozza, Andrea; De Silvestro, Giustina
title: The true historical origin of convalescent plasma therapy
date: 2020-06-12
journal: Transfus Apher Sci
DOI: 10.1016/j.transci.2020.102847
sha: abe9c2c4748905b7058f66a4be80ece33b54eb27
doc_id: 980312
cord_uid: wqc4o648

nan

New York outbreak of poliomyelitis [8] . Again in 1916, Nicolle and Conseil applied serotherapy to contain a small measles epidemic in Tunis [9] . In 1915 Hess used the same therapeutic option to treat mumps and prevent its testicular complications [10] . Finally, the Italian Francesco Cenci is credited to be the first to use convalescent serum as a therapeutic tool, to protect children exposed to measles infection [11] .

It was possible to get the original article by Cenci [12] , published in 1907 in an Italian pediatric journal (Fig. 1) . The author was a public health doctor working in a small town of Central Italy near Perugia (Campello sul Clitunno, about 1,800 inhabitants in the early twentieth century [13] ). Starting from the observation that, once cured of measles, it is very unlikely that a patient will fall ill a second time, and thus presuming the existence of some serum protective factor, during an epidemic outbreak in 1901 Cenci practiced a bloodletting of 600 mL to a 20-year old man, three weeks after recovery from measles. After blood coagulation, he collected serum in three sterilized tubes, adding a solution of phenic acid as a protective agent. The convalescent serum was then inoculated to four children aged between 4 and 8 years, who did not contract measles after this treatment, unlike their cohabitant siblings. It has to be noticed that, to ensure safety of the product, 60 hours before administration to patients, a portion of serum was inoculated into the peritoneum of a rabbit and also into the arm of Cenci himself, without this causing general or local reactions.

In these cases, however, human convalescent serum was successfully used as a prophylactic agent. This prophylactic application lasted several decades, as measles had a high mortality (6-7%) in some populations [14] .

In December 1906, there was another outbreak of measles in the Campello sul Clitunno area, with about forty sick children. Cenci successfully repeated prophylaxis through the convalescent serum inoculation. Moreover, in a child with a severe form of measles with pneumonia serotherapy made infection milder and duration of the disease shorter. This case unequivocally represents a therapeutic and not only prophylactic use of the convalescent serum, probably for the first time.

As a matter of facts, Cenci reported that a similar treatment had been made on two children in 1900, in the Pediatric Clinic of Rome directed by Luigi Concetti [15] , that was the first to use serotherapy against diphtheria in Italy, after the seminal studies by Emil Behring and Shibasaburo Kitasato [16] . Evidently, this therapeutic innovation was soon put into practice in an Italian suburban area, suggesting already then a good public health system. In fact, it may seem singular that this pioneering investigation was fully performed outside academic or research centres, and moreover in a deeply rural area of Italy, but it is well known that intuition and experimentalism at that time were typical of the whole medical class, which still breathed the cultural ground of the nineteenth century, namely a truly innovative period in the history of medicine.

J o u r n a l P r e -p r o o f

Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow

Convalescent plasma, an apheresis research project targeting and motivating the fully recovered COVID 19 patients: a rousing message of clinical benefit to both donors and recipient alike

Treatment for emerging viruses: convalescent plasma and COVID-19

Convalescent plasma: possible therapy for novel coronavirus disease 2019

Collecting and evaluating convalescent plasma for COVID-19 tratment: why and how? Vox Sang

Convalescent plasma transfusion for the treatment of COVID-19: systematic review

Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H%N1 treatment?

Before the vaccines: medical treatments of acute paralysis in the 1916 New York epidemic of poliomyelitis

Pouvoir preventif du serum d'un malade convalescent de rougeole

A protective therapy for mumps

Alcune esperienze di sieroimmunizzazione e sieroterapia nel morbillo

ISTAT data

Return to the past: the case for antibody-based therapies in infectious diseases

III Rendiconto statistico-clinico del biennio 1898-99 e 1899-1900

Emil Behring's medical culture: from disinfection to serotherapy

J o u r n a l P r e -p r o o f Cenci, 1907 [12]